Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

France Nouvelles Nouvelles

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
France Dernières Nouvelles,France Actualités
  • 📰 Nature
  • ⏱ Reading Time:
  • 20 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 68%

Nature research paper: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

and is provided in this format here as a response to the exceptional public-health crisis. This accepted manuscript will continue through the processes of copy editing and formatting to publication of a finalized version of record on nature.com. Please note there may be errors present in this version, which may affect the content, and all legal disclaimers apply.

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, 15 of which are in the receptor-binding domain , thereby raising concerns about the effectiveness of available vaccines and antibody therapeutics. Here, we show that the Omicron RBD binds to human ACE2 with enhanced affinity, relative to the Wuhan-Hu-1 RBD, and binds to mouse ACE2.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Nature /  🏆 64. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shiftNature research paper: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Lire la suite »

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesNature research paper: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Lire la suite »

A new tool to probe SARS-CoV-2 variantsA new tool to probe SARS-CoV-2 variantsVirus-like particles offer a new way to investigate genetic variation in SARSCoV2. Learn more in a new SciencePerspective:
Lire la suite »

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19A new Science study details PF-07321332, an orally active, small-molecule inhibitor of the SARSCoV2 main protease, a key viral target. In a phase I clinical trial, it achieved concentrations expected to inhibit the virus based on in vitro studies. pfizer
Lire la suite »

SARS-CoV-2 infection in free-ranging white-tailed deer - NatureNature - <ArticleTitle Language="En" xml:lang="en">SARS-CoV-2 infection in free-ranging white-tailed deer</ArticleTitle>
Lire la suite »

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shiftNature research paper: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Lire la suite »



Render Time: 2025-04-23 19:50:12